Evidence map›Paper›PMID 38873035›Full record

ArticleJournal of cellular immunology2024

The Natural History of Post-Chikungunya Viral Arthritis Disease Activity and T-cell Immunology: A Cohort Study.

Aileen Yu-Hen Chang, Alfonso Sucerquia Hernández, Jose Forero Mejía, Sarah Renee Tritsch, Evelyn Mendoza-Torres, Liliana Encinales, Andres Cadena Bonfanti, Abigale Marie Proctor, Gary Leonard Simon, Samuel Joseph Simmens and 1 more

Abstract read
In one paragraph

Article in Journal of cellular immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aileen Yu-Hen ChangDepartment of Medicine, George Washington University, Washington, DC, USA.
Alfonso Sucerquia HernándezDepartment of Medicine, George Washington University, Washington, DC, USA.
Jose Forero MejíaDepartment of Medicine, George Washington University, Washington, DC, USA.
Sarah Renee TritschDepartment of Global Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Evelyn Mendoza-TorresAdvanced Biomedicine Research Group, Universidad Libre de Colombia, Seccional Barranquilla, Barranquilla, Atlántico, Colombia.
Liliana EncinalesDepartment of Medicine, Allied Research Society, Barranquilla, Atlántico, Colombia.
Andres Cadena BonfantiCentro de Investigación, Clínica de la Costa SAS, Barranquilla, Atlántico, Colombia.
Abigale Marie ProctorDepartment of Global Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Gary Leonard SimonDepartment of Medicine, George Washington University, Washington, DC, USA.
Samuel Joseph SimmensDepartment of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Gary Steven FiresteinDepartment of Medicine, UC San Diego School of Medicine, San Diego, CA, USA.

Funding

The role of IL-2 therapy for Relapsing-Remitting Chikungunya ArthritisK23AR076505 · NIAMS · GEORGE WASHINGTON UNIVERSITY · PI CHANG, AILEEN · 2020 to 2022
$466k
NIAMS NIH HHS K23 AR076505
6 · The paper itself

Abstract

Background: Chikungunya virus (CHIKV) is an alphavirus spread by mosquitos that causes arthralgias and arthritis that may last for years. The objective of this study was to describe the arthritis progression and T cell immunology over a two-year period. Methods: A cohort of 40 cases of serologically confirmed CHIKV from Magdalena and Atlántico, Colombia were followed in 2019 and again in 2021. Arthritis disease severity, disability, pain, stiffness, physical function, mobility, fatigue, anxiety, sleep disturbances and depression were assessed. Serum cytokines and T-cell subsets were measured and tested for change. Correlations within each of the 2 time periods for laboratory parameters were also examined. Results: Although, arthritis disease severity, as measured by the Disease Activity Score-28 (DAS-28) did not change significantly over a two-year period, a new metric- the Chikungunya Disease Activity Score (CHIK-DAS)- was more sensitive to detect changes in disease severity than the Disease Activity Score-28 (DAS-28) and showed some improvement in average disease severity from moderate to mild over two years. Cases were characterized by moderate disability, pain, and stiffness with mild alterations of physical function, mobility, fatigue, anxiety, sleep disturbances and depression that did not change significantly over time. Small joints including the fingers and wrists were most affected without significant change over time. The percentage of effector T cells (Teffs) and regulatory T cells (Tregs) of CD4 Conclusions: The presented data suggest that arthritis persists almost seven years after chikungunya infection in some patients with waning Teff and Treg numbers and activation markers over time. Treg activation may be a promising therapeutic target for further investigation.

Indexed as

ArthritisArthritis disease severityChikungunya virusDisabilityPainStiffnessT-cell populations

Identifiers

PMID38873035
PMCPMC11172407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.